Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Chief Operating Officer | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tarsus Pharmaceuticals, Inc.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,532 |
Reported balance
After 2026-09-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-04 · Sale · Disposed 4,564 · Balance 78,532 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2: Includes 305 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy daughter | 475 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 475 F3: This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
F2: Includes 305 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
F3: This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 9, 2026 20:12 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,564 | $85.00 | $387,940.00 |
DisclosureSEC source: 0001827584-26-000013 · wk-form4_1788984767.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,532 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · balance_after: Includes 305 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,989 | $66.75 | $199,515.75 |
DisclosureSEC source: 0001827584-26-000011 · wk-form4_1774386340.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,791 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 23:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,589 | $67.00 | $307,463.00 |
DisclosureSEC source: 0001827584-26-000009 · wk-form4_1773961468.xml · nonDerivative · entry 3 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,780 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 23:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,610 | $68.71 | $248,043.10 |
DisclosureSEC source: 0001827584-26-000009 · wk-form4_1773961468.xml · nonDerivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,369 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 23:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,125 | $69.42 | $216,937.50 |
DisclosureSEC source: 0001827584-26-000009 · wk-form4_1773961468.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,979 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:35 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 5,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · derivative · entry 6 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,067 Underlying: Common Stock · 5,022 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. F7 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:35 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · derivative · entry 5 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,040 Underlying: Common Stock · 8,020 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:35 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · derivative · entry 4 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,148 Underlying: Common Stock · 8,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:35 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 5,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · derivative · entry 3 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:35 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 26,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 17,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001827584-26-000005 · wk-form4_1773086795.xml · derivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,161 Underlying: Common Stock · 17,161 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 27,310 | $0.00 Strike: $74.90 | $0.00 |
DisclosureSEC source: 0001827584-26-000005 · wk-form4_1773086795.xml · derivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,310 Underlying: Common Stock · 27,310 shares Expires 2036-03-04 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,366 | $76.67 | $641,421.22 |
DisclosureSEC source: 0001827584-26-000002 · wk-form4_1772744614.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,817 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:09 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GiftCommon Stock | 475 | $0.00 | $0.00 |
DisclosureSEC source: 0001827584-25-000003 · wk-form4_1766092157.xml · nonDerivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By daughter Disclosed balance after: 475 F2 · kind: This transaction involved the Reporting Person's gift of 475 shares of common stock to his daughter who shares Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:09 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GiftCommon Stock | 950 | $0.00 | $0.00 |
DisclosureSEC source: 0001827584-25-000003 · wk-form4_1766092157.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,183 F1 · balance_after: Includes 451 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 01:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,435 | $50.11 | $122,017.85 |
DisclosureSEC source: 0001819790-25-000058 · wk-form4_1742521768.xml · nonDerivative · entry 3 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,682 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,543 | $47.40 | $120,538.20 |
DisclosureSEC source: 0001819790-25-000058 · wk-form4_1742521768.xml · nonDerivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,117 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 18, 2025 Filed Mar 21, 2025 01:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,605 | $46.29 | $120,585.45 |
DisclosureSEC source: 0001819790-25-000058 · wk-form4_1742521768.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,660 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:39 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000043 · wk-form4_1742348347.xml · derivative · entry 4 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,060 Underlying: Common Stock · 8,019 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:39 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000043 · wk-form4_1742348347.xml · derivative · entry 3 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,296 Underlying: Common Stock · 8,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:39 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 5,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000043 · wk-form4_1742348347.xml · derivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,097 Underlying: Common Stock · 5,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:39 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 21,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-25-000043 · wk-form4_1742348347.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 1,234 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 20,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000025 · wk-form4_1741382334.xml · derivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,089 Underlying: Common Stock · 20,089 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 30,628 | $0.00 Strike: $44.54 | $0.00 |
DisclosureSEC source: 0001819790-25-000025 · wk-form4_1741382334.xml · derivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,628 Underlying: Common Stock · 30,628 shares Expires 2035-03-04 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 23:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,879 | $30.60 | $149,297.40 |
DisclosureSEC source: 0001819790-24-000043 · wk-form4_1710889381.xml · nonDerivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,767 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000043 · wk-form4_1710889381.xml · derivative · entry 4 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,444 Underlying: Common Stock · 8,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 5,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000043 · wk-form4_1710889381.xml · derivative · entry 3 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,194 Underlying: Common Stock · 5,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 13,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000043 · wk-form4_1710889381.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 1,705 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:10 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 32,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000031 · wk-form4_1710191431.xml · derivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,079 Underlying: Common Stock · 32,079 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:10 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 47,500 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001819790-24-000031 · wk-form4_1710191431.xml · derivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:56 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 390 | $12.15 | $4,738.50 |
DisclosureSEC source: 0001827584-23-000004 · wf-form4_167961578319952.xml · nonDerivative · entry 3 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,696 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:56 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 379 | $12.64 | $4,790.56 |
DisclosureSEC source: 0001827584-23-000004 · wf-form4_167961578319952.xml · nonDerivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,086 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:56 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 372 | $12.89 | $4,795.08 |
DisclosureSEC source: 0001827584-23-000004 · wf-form4_167961578319952.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,465 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 23:12 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 380 | $12.61 | $4,791.80 |
DisclosureSEC source: 0001827584-23-000002 · wf-form4_167944035754056.xml · nonDerivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,837 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:12 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 360 | $13.28 | $4,780.80 |
DisclosureSEC source: 0001827584-23-000002 · wf-form4_167944035754056.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,217 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 22:15 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 357 | $13.43 | $4,794.51 |
DisclosureSEC source: 0001209191-23-019876 · doc4.xml · nonDerivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,577 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:15 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 5,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019876 · doc4.xml · derivative · entry 3 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,291 Underlying: Common Stock · 5,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:15 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 5,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-019876 · doc4.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 32,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018001 · doc4.xml · derivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,592 Underlying: Common Stock · 32,592 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 48,116 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018001 · doc4.xml · derivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,116 Underlying: Common Stock · 48,116 shares Expires 2033-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 8, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 20,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001827584-22-000002 · wf-form4_164703341053306.xml · derivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,388 Underlying: Common Stock · 20,388 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 69,498 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0001827584-22-000002 · wf-form4_164703341053306.xml · derivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,498 Underlying: Common Stock · 69,498 shares Expires 2032-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:57 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 61,499 | $0.00 Strike: $47.25 | $0.00 |
DisclosureSEC source: 0001209191-21-002744 · doc4.xml · derivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,499 Underlying: Common Stock · 61,499 shares Expires 2031-01-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on January 7, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.